Physician profile
David Michael Schultz
NPI 1386646214
$720.52
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $273 · 2021: $18.27.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $179.85 | 2019-2020 | |
| Pfizer INC. | $155.46 | 2019 | |
| Adlon Therapeutics L.P. | $38.65 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.44 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $36.80 | 2020 | |
| Novo Nordisk INC | $36.51 | 2020 | |
| Amgen INC. | $32.93 | 2019 | |
| Genentech USA, INC. | $32.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.83 | 2019 | |
| Abbvie INC. | $18.27 | 2021 | |
| Vanda Pharmaceuticals INC. | $18.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.04 | 2019 | |
| Astellas Pharma US INC | $17.40 | 2020 | |
| Strongbridge US INC. | $17.19 | 2019 | |
| Sanofi Pasteur INC. | $14.99 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.78 | 2019 | |
| Boston Scientific Corporation | $11.61 | 2019 | |
| Merck Sharp & Dohme LLC | $11.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.